Insider trading

Period: 120 months Stock: LH Plan: Not stated × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

91 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

91 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

91 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

91 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
91 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
91 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

91 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
21 Feb 2023
Kirchgraber Paul R CEO, Covance Drug Development
Sold, plan not stated
$2.00M 8,000 at 250.58
46.9%
14 Feb 2023
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$76.52K 309 at 247.63
4.4%
7 Feb 2023
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$99.39K 409 at 243.01
5.8%
7 Feb 2023
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$53.22K 219 at 243.01
3.9%
3 Feb 2023
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$82.26K 324 at 253.90
4.6%
3 Feb 2023
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$43.92K 173 at 253.90
3.1%
8 Nov 2022
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$259.66K 1,116 at 232.67
14.3%
26 Sep 2022
EISENBERG GLENN A Chief Financial Officer, EVP
Sold, plan not stated 4×
$5.27M 25,000 at 210.62
47.9%
7 Sep 2022
Caveney Brian J EVP, President of Diagnostics
Bought
$10.25K 44 at 231.20
0.3%
Largest buy in 3 yrs
3 Aug 2022
EISENBERG GLENN A Chief Financial Officer, EVP
Sold, plan not stated 3×
$8.15M 32,100 at 253.94
38.1%
1 Aug 2022
Wilkinson Peter J SVP, Chief Accounting Officer
Sold, plan not stated 3×
$665.63K 2,576 at 258.40
57.7%
Sold half or more
7 Jun 2022
Caveney Brian J EVP, President of Diagnostics
Bought
$10.17K 42 at 242.19
0.3%
First buy on file
29 Mar 2022
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$678.64K 2,449 at 277.11
31.7%
29 Mar 2022
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$652.87K 2,356 at 277.11
26.3%
25 Mar 2022
Sold, plan not stated
$156.14K 572 at 272.98
8.2%
10 Mar 2022
Summy Amy B. EVP, Chief Marketing Officer
Sold, plan not stated
$65.29K 249 at 262.21
49.9%
16 Feb 2022
NEUPERT PETER M Director
Bought 3×
$922.82K 3,500 at 263.66
51.8%
First buy on file
15 Feb 2022
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$56.71K 207 at 273.98
3.0%
15 Feb 2022
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$56.71K 207 at 273.98
3.8%
7 Feb 2022
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$60.47K 218 at 277.38
4.0%
7 Feb 2022
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$56.59K 204 at 277.38
3.0%
3 Feb 2022
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$46.75K 172 at 271.81
3.2%
3 Feb 2022
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$43.76K 161 at 271.81
2.5%
15 Dec 2021
Sold, plan not stated 4×
$151.13K 500 at 302.26
7.4%
15 Sep 2021
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$1.34M 4,500 at 296.78
46.1%
7 Jun 2021
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$1.20M 4,500 at 266.56
46.2%
6 May 2021
Kirchgraber Paul R CEO, Covance Drug Development
Sold, plan not stated
$691.38K 2,500 at 276.55
24.2%
3 May 2021
Sold, plan not stated
$699.80K 2,600 at 269.16
14.3%
30 Mar 2021
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$204.53K 812 at 251.88
13.4%
30 Mar 2021
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$168.00K 667 at 251.88
11.8%
18 Feb 2021
Wilkinson Peter J SVP, Chief Accounting Officer
Sold, plan not stated
$559.59K 2,317 at 241.51
87.1%
Sold half or more
16 Feb 2021
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated 3×
$49.20K 208 at 236.55
4.5%
16 Feb 2021
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated 2×
$44.57K 188 at 237.06
4.2%
5 Feb 2021
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$45.85K 203 at 225.85
4.7%
5 Feb 2021
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$24.62K 109 at 225.85
2.5%
6 Nov 2020
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$126.18K 588 at 214.59
13.0%
4 Nov 2020
Kirchgraber Paul R CEO, Covance Drug Development
Sold, plan not stated
$321.20K 1,500 at 214.14
16.3%
8 Jul 2020
Sold, plan not stated
$225.06K 1,300 at 173.12
20.3%
2 Jul 2020
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated
$73.95K 435 at 170.00
9.7%
24 Jun 2020
van der Vaart Sandra D EVP, Chief Legal Officer
Sold, plan not stated 2×
$139.81K 872 at 160.33
16.3%
5 May 2020
KING DAVID P Director
Sold, plan not stated
$5.00M 31,250 at 160.00
9.1%
10 Mar 2020
Seltz Judith C EVP, CHRO
Bought
$55.62K 330 at 168.56
132%
First buy on file
28 Feb 2020
Seltz Judith C EVP, CHRO
Bought
$43.74K 250 at 174.94
opened
First buy on file
21 Feb 2020
Wilkinson Peter J SVP, Chief Accounting Officer
Sold, plan not stated
$56.33K 297 at 189.65
50.0%
Sold half or more
19 Feb 2020
Sold, plan not stated
$5.02M 26,479 at 189.76
64.3%
Sold half or more
13 Feb 2020
Sold, plan not stated
$231.28K 1,227 at 188.49
19.4%
13 Feb 2020
van der Vaart Sandra D SVP, Global General Counsel
Sold, plan not stated 2×
$39.21K 208 at 188.49
7.1%
13 Feb 2020
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated 2×
$35.44K 188 at 188.49
27.9%
10 Feb 2020
van der Vaart Sandra D SVP, Global General Counsel
Sold, plan not stated
$24.20K 133 at 181.99
5.0%
10 Feb 2020
Schroeder Mark S EVP, President-Diagnostics Lab
Sold, plan not stated
$19.65K 108 at 181.99
26.4%
Showing 1–50 of 91. Page 1 of 2 Older →